BioMedNewsBreaks

TuesdayAug 03, 2021 1:24 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured on The Dealmaker Show, to Present at Canaccord Genuity Annual Growth Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was featured on The Dealmaker Show, a fast-paced and high-energy forum hosted by bestselling author Oren Klaff. Tryp’s CEO and Chairman Greg McKee joined the latest episode to discuss the company’s focus on psychedelics, how he got involved with Tryp and what opportunities the company sees in the psychedelics space. “It’s really simple. There are a lot of naturally derived chemistries around that eventually find their way into more traditional drug development pathways. Psychedelics are some…

Continue Reading

FridayJul 30, 2021 12:03 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Developing, Delivering New Generation of MedTech Solutions for Brain Diagnostics Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, recently announced its entry into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric motion technology. The merger is anticipated to expand the market footprint both for Brain Scientific and Piezo Motion, as well as the potential to deliver innovative technologies to high-growth sectors. Dr. Baruch Goldstein, founder of Brain Scientific, was quoted in a recent article as saying, “Together, we plan to achieve rapid expansion while delivering and developing the new generation of MedTech solutions for the brain diagnostics…

Continue Reading

ThursdayJul 29, 2021 12:26 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Opening of Denver-Based State-of-the-Art International Training Center

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced that it has opened the Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and training to dentists, dental teams and other health care providers in a live and hands-on setting. The Institute’s emphasis will focus on educating health care providers about OSA, Vivos’ treatments for OSA within their practice areas and providing training on Vivos’ related practice management tools…

Continue Reading

WednesdayJul 28, 2021 12:09 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Clear Opportunity to Bring Impactful Therapy to GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. Over recent months, the company has achieved several milestones demonstrating its operational, financial and strategic strengths and continuous de-risking of its lead candidate Berubicin clinical program. “The company has begun a pivotal Phase 2 clinical trial evaluating the efficacy and safety of Berubicin for recurrent adult glioblastoma multiforme (‘GBM’). Enrollment in the clinical trial is already underway, with patient dosing set to begin in Q3 2021,” reports an article discussing the status of…

Continue Reading

WednesdayJul 28, 2021 10:43 am

BioMedNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Acquisition Target Identifies Breakthrough COVID-19 Detection Biosensor Candidates

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, today announced that its acquisition target, 3a-diagnostics GmbH (“3a”), has identified the first saliva activated “in-mouth” biosensor candidates for the detection of a COVID-19 infection. According to the update, the enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications for the rapid detection of infectious diseases including COVID-19 at home or at the point-of-care. “We believed in 3a’s research and development plan from the beginning, when we signed the first collaboration contract in 2020. Now that XPhyto has announced the pending acquisition of 3a,…

Continue Reading

TuesdayJul 27, 2021 3:44 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation solutions and stability services so the company can rapidly provide clinical-trial-ready formulations to its customers. The lab will also be utilized to produce proprietary media used in its chromatography kits. A recent article reads, “Dr. Larry DeLucas, VP of Operations at Predictive Oncology, said he…

Continue Reading

TuesdayJul 27, 2021 11:42 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Manufacture of Synthetic Ibogaine Moves to Second Stage

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has begun the second stage of manufacturing pharmaceutical-grade ibogaine to be used in clinical research. According to the announcement, this stage will focus on assessing the quality of MINDCURE’s synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing. The company intends to manufacture pharmaceutical-grade ibogaine to provide researchers with a consistent supply of sustainable, high-quality, reliable psychedelic substance. The company has already filed patent applications for two routes of chemical synthesis of ibogaine, with both…

Continue Reading

MondayJul 26, 2021 10:30 am

BioMedNewsBreaks – Avricore Health Inc.’s (TSX.V: AVCR) (OTCQB: AVCRF) HealthTab(TM) Adds ID Now(TM) Molecular Test Device to Abbott Distribution Agreement

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) today announced the signing of the first amendment to its supplier distribution agreement between HealthTab(TM) Inc., a wholly owned subsidiary, and Abbott, a global health care company and diagnostics leader in Canada. According to the update, the agreement, first signed on May 31, 2021, allows HealthTab(TM) to distribute in Canada Abbott’s Afinion(TM) 2, as well as associated tests for diabetes and heart-disease screening in community pharmacies. This includes HbA1c testing, which lead to the subsequent signing of a master agreement with Shoppers Drug Mart to bring this new testing to select locations as an…

Continue Reading

FridayJul 23, 2021 11:13 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Poised as Key Innovative Leader at Forefront in Neurology Tech

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is a recognized leading innovative player in the brain monitoring space. The company continues to be at the forefront of what is next in neurology technology. In a Tech Times feature, Brain Scientific’s Marketing Director Irina Nazarova outlined key brain monitoring trends to watch in 2021, including the fact that brain monitoring is becoming as popular and widespread as monitoring pulse or heart rate. Several potential applications have swelled, and EEG monitoring is no longer a preserve of clinicians and expert neuroscientific researchers. A recent article…

Continue Reading

FridayJul 23, 2021 10:53 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Looking to Unlock Additional Value with Russell 2000 Index Inclusion

CNS Pharmaceuticals (NASDAQ: CNSP), a pharmaceutical company enthusiastically pursuing enrollment of about 243 brain cancer patients in a clinical trial designed to analyze the efficacy and safety of its lead drug candidate, was selected to be added to the Russell 2000 Index effective June 25. A subset of the Russell 3000 Index, the Russell 2000 Index is a measure of the performance of the small-cap segment of the U.S. equity market. Per CNS Pharmaceuticals CEO John Climaco, quoted in a recent article, the company was pleased to meet this noteworthy milestone. He said, “As our team continues to drive our…

Continue Reading